Fulcrum Therapeutics stock soars ahead of sickle cell trial data

Published 28/07/2025, 21:08
© Reuters.

Investing.com -- Fulcrum Therapeutics (NASDAQ:FULC) stock rose 20% after the company announced plans to present topline results from the 12 mg dose cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease.

The clinical-stage biopharmaceutical company will host a conference call and webcast on Tuesday, July 29, 2025, at 8:00 a.m. ET to discuss the findings. Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Dr. Wally Smith, Director at the VCU Adult Sickle Cell Program.

Fulcrum Therapeutics focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases. The upcoming presentation of the PIONEER trial results represents a significant milestone in the company’s development of pociredir as a potential treatment for sickle cell disease.

Investors responded positively to the announcement, driving the stock up substantially in anticipation of the data presentation. The significant share price movement reflects market interest in the company’s progress with its sickle cell disease treatment candidate.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.